尼妥珠单抗联合同步放疗在宫颈癌治疗中对miR-196a、miR-130a表达的影响研究  

Study on the effect of nituzumab combined with synchronous radiotherapy on the expression of miR-196a and miR-130a in cervical cancer therapy

作　　者：孙玉红 秦彦芹 李守勋 SUN Yuhong;QIN Yanqin;LI Shouxun(Department of Gynecology,Lanshan District People's Hospital of Rizhao City,Rizhao,Shandong,276807,China)

机构地区：[1]日照市岚山区人民医院妇科,山东日照276807

出　　处：《当代医学》2023年第12期31-36,共6页Contemporary Medicine

摘　　要：目的探讨尼妥珠单抗联合同步放疗在宫颈癌治疗中的疗效分析及对miR-196a、miR-130a表达的影响。方法选取2015年1月至2016年6月本院收治的106例宫颈癌患者作为研究对象,随机分为对照组与研究组,每组53例。对照组给予常规化疗及三维后装腔内放射治疗,研究组在对照组治疗基础上给予尼妥珠单抗治疗。比较两组肿瘤控制率、不良反应发生情况及治疗前后miR-196a、miR-130a表达水平、免疫功能(CD3^(+)、CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+))、肿瘤标志物[癌抗原153(CA153)、糖类抗原199(CA199)、癌胚抗原(CEA)]、生存情况[中位总生存期(OS)、中位无进展生存期(PFS)]。结果研究组肿瘤控制率为90.57%,高于对照组的75.47%,差异有统计学意义(P<0.05)。治疗前,两组miR-196a、miR-130a表达水平比较差异无统计学意义;治疗后,两组miR-196a、miR-130a表达水平均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05)。治疗后,两组CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)均低于治疗前,CD8^(+)高于治疗前,差异有统计学意义(P<0.05)。治疗前后,两组CD3^(+)、CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+)比较差异无统计学意义。治疗前,两组血清CA153、CA199、CEA水平比较差异无统计学意义;治疗后,两组血清CA153、CA199、CEA水平均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05)。两组血小板减少、血红蛋白减少、消化道损伤、呕吐恶心Ⅰ~Ⅱ、Ⅲ~Ⅳ发生率比较差异无统计学意义。研究组中位PFS、中位OS均长于对照组,差异有统计学意义(P<0.05)。结论尼妥珠单抗联合同步放疗治疗宫颈癌患者,有利于下调miR-196a、miR-130a表达,提高肿瘤控制率,延长患者生存期,且安全性较高。Objective To investigate the efficacy of nituzumab combined with synchronous radiotherapy in the treatment of cervical cancer and the effect on the expression of miR-196a and miR-130a.Methods 106 patients with cervical cancer admitted to our hospital from January 2015 to June 2016 were selected as the research subjects,and they were randomly divided into the control group and study group,with 53 cases in each group.The control group was given conventional chemotherapy and three-dimensional post-capsular radiotherapy,and the study group was given nituzumab on the basis of the control group.The tumor control rate,occurrence of adverse reactions,expression levelsof miR-196a and miR-130a,immune function(CD3^(+),CD4^(+),CD8^(+),CD4^(+)/CD8^(+))and tumor markers(cancer antigen 153[CA153],carbohydrate antigen 199[CA199],carcinoembryonic antigen[CEA]),survival(median overall survival[OS]and median progression-free survival[PFS])before and after treatment were compared between the two groups.Results The tumor control rate in the study group was 90.57%,which was higher than 75.47%in the control group,the difference was statistically significant(P<0.05).Before treatment,there were no significant differences in the expression levels of miR-196a and miR-130a between the two groups;after treatment,the expression levels of miR-196a and miR-130a of the two groups were lower than before treatment,and the study group was lower than the control group,the differences were statistically significant(P<0.05).After treatment,levels of CD3^(+),CD4^(+)and CD4^(+)/CD8^(+)of the two groups were lower than before treatment,and the level of CD8^(+)were higher than before treatment,the differences were statistically significant(P<0.05);before and after treatment,there were no significant differences in levels of CD3^(+),CD4^(+),CD8^(+)and CD4^(+)/CD8^(+)between the two groups.Before treatment,there was no significant difference in the serum levels of CA153,CA199 and CEA between the two groups;after treatment,the serum levels of CA153,CA199 and

关 键 词：宫颈癌 三维后装腔内放射治疗 尼妥珠单抗 miR-196a miR-130a 

分 类 号：R737.33[医药卫生—肿瘤]